Arcutis Biotherapeutics, Inc.
ARQT
$21.69
$1.266.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 69.64% | 29.17% | 83.72% | 7.21% | 26.28% |
| Total Depreciation and Amortization | 2,311.76% | 774.86% | 18.96% | 270.03% | -95.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.90% | 4.20% | 20.61% | -3.69% | 16.42% |
| Change in Net Operating Assets | 220.18% | -225.01% | -481.27% | 58.56% | 25.48% |
| Cash from Operations | 100.72% | 3.87% | 98.67% | 21.13% | 32.14% |
| Capital Expenditure | -- | -- | 100.00% | -123.44% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 128.17% | 143.06% | 156.09% | 86.17% | -169.51% |
| Cash from Investing | 128.04% | 140.95% | 156.08% | 86.12% | -169.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -5.15% | -99.76% | -97.39% | -54.56% | 36.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -5.15% | -99.76% | -198.11% | -54.56% | 36.36% |
| Foreign Exchange rate Adjustments | 869.23% | 105.48% | -444.12% | 230.67% | -388.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.26% | -117.98% | -233.02% | 2,045.99% | -546.36% |